Role of fibroblast growth factor-23 in renal disease activity and bone density involvement in patients with lupus nephritis

Table 7 Correlation of fibroblast growth factor-23 with the other variables, n (%)

Variables	Fibroblast growth factor-23
Age (years)	-0.01 (0.90)
Body mass index (kg/m2)	0.03 (0.75)
Duration	-0.14 (0.20)
Random blood sugar (mg/dL)	-0.10 (0.34)
Hemoglobin (g/dL)	-0.03 (0.79)
Leucocytes (103/μL)	0.13 (0.13)
Platelets (103/μL)	0.12 (0.82)
Neutrophil/Lymphocyte ratio	-0.15 (0.17)
Platelets/Lymphocytes ratio	-0.19 (0.20)
Blood urea nitrogen (mg/dL)	0.10 (0.34)
Creatinine (μmol/L)	0.21 (0.06)
Proteinuria (mg/day)	0.01 (0.26)
Glomerular filtration rate (mL/minute/1.73 m2)	0.09 (0.51)
Urine analysis
Hematuria (HPF)	0.06 (0.53)
Pyuria (HPF)	-0.04 (0.77)
Albuminuria	-0.18 (0.48)
Coagulation profile
Prothrombin time (seconds)	-0.02 (0.86)
Prothrombin concentration (%)	-0.15 (0.17)
International randomized ratio	0.10 (0.34)
Bone parameters
Calcium (mg/dL)	0.14 (0.26)
Phosphorus (mg/dL)	0.12 (0.51)
Parathormone (pg/mL)	-0.11 (0.08)
Vitamin D (ng/mL)	0.12 (0.53)
Alkaline phosphatase (U/L)	-0.19 (0.17)
Complement
C3 (mg/dL)	-0.14 (0.92)
C4 (mg/dL)	-0.08 (0.48)
Echocardiography
Ejection fraction (%)	0.10 (0.38)
Left ventricular end diastolic diameter (cm)	0.03 (0.76)
Left ventricular end systolic diameter (cm)	-0.18 (0.10)
Pulmonary artery systolic pressure (mmHg)	-0.05 (0.62)
Dual-energy X-ray absorptiometry scan (g/cm2)	-0.67 (0.001)

HPF: High-power field.